Clinical trials: CMV Disease
Cytomegalovirus Infection, GVHD
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
This study in a cohort of allo-HSCT recipients aims to validate the suitability of an improved T-Track® CMV assay to assess the functionality of CMV protein-reactive effector cells and its suitability to determine cut-off values…
- Trial name
- AlloProtectCMV (NCT02156479)
- Where
- Germany
- Volunteers
- 175 people
- Sponsor
- Lophius Biosciences GmbH
Infection
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- CHARMS (NCT02108522)
- Testing
- Multivirus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- AlloVir
Cytomegalovirus Retinitis, HIV Infections
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002156
- Testing
- Fomivirsen sodium, Ganciclovir
- Where
- 18 sites in United States
- Volunteers
- 194 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Infections, HIV Infections
A Study of Lobucavir in Patients With AIDS
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
- Trial name
- NCT00002352
- Testing
- Lobucavir
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Cytomegalovirus Infections
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid organ transplant recipients. The anticipated time on study treatment is 3-12 months and the target sample size is less than 100…
- Trial name
- NCT00090766
- Testing
- valganciclovir [Valcyte]
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Adenovirus Infections, Cytomegalovirus Infection
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks…
- Trial name
- ATHENA (NCT04706923)
- Testing
- BCV
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- SymBio Pharmaceuticals
Cytomegalovirus Infections
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
This 2 arm study will compare the efficacy of 100 days of Valcyte (900mg po daily) prophylaxis with that of no prophylaxis, under the condition of pre-emptive therapy of active CMV infection, in CMV positive renal transplant…
- Trial name
- NCT00372229
- Testing
- Valganciclovir CMV Prophylaxis, Valganciclovir (Pre-emptive CMV Therapy), Ganciclovir
- Where
- 24 sites in Austria, Germany
- Volunteers
- 299 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Retinitis, HIV Infections
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients.
- Trial name
- NCT00002034
- Testing
- Zidovudine, Ganciclovir
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Retinitis, HIV Infections
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune adjuvant in HIV-seropositive patients.
- Trial name
- NCT00002321
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
Cytomegalovirus Retinitis, HIV Infections
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
- Trial name
- NCT00002187
- Testing
- Fomivirsen sodium
- Where
- 17 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Infections
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in cytomegalovirus (CMV)-seronegative recipients of a…
- Trial name
- NCT01753167
- Testing
- MCMV3068A, MCMV5322A
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Cytomegalovirus Infections
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
- Trial name
- SPYVAC01 (NCT06145178)
- Testing
- SPYVAC01
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SpyBiotech Limited